CH CRL (R4)
0.9.0 - Draft

This page is part of the CH CRL (R4) (v0.9.0: STU Draft) based on FHIR R4. . For a full list of available versions, see the Directory of published versions

Table of Contents

..0 Table of Contents
...1 Home
...2 Use Case
...3 Logical Model
...4 FHIR Document (Bundle)
...5 Profiles
...6 Extensions
...7 Terminology
...8 Change Log
...9 Artifacts Summary
....9.1 CH CRL Cancer Report Logical Model
....9.2 CH CRL Bundle
....9.3 CH CRL Communication
....9.4 CH CRL Composition
....9.5 CH CRL Condition Disease
....9.6 CH CRL Condition Final Cause of Death
....9.7 CH CRL DocumentReference
....9.8 CH CRL Encounter Treatment Decision
....9.9 CH CRL Observation α-fetoprotein
....9.10 CH CRL Observation Ann Arbor Staging
....9.11 CH CRL Observation Associated In-situ Tumour
....9.12 CH CRL Observation Binet Staging
....9.13 CH CRL Observation Breslow Thickness
....9.14 CH CRL Observation cM
....9.15 CH CRL Observation cN
....9.16 CH CRL Observation COG ALL Staging
....9.17 CH CRL Observation COG Staging
....9.18 CH CRL Observation cT
....9.19 CH CRL Observation Cerebrovascular Accident or Transient Ischemic Attack
....9.20 CH CRL Observation Charlson Index
....9.21 CH CRL Observation Chronic Pulmonary Disease
....9.22 CH CRL Observation Circumferential Resection Margins
....9.23 CH CRL Observation Clinical Tumour Size
....9.24 CH CRL Observation Congestive Heart Failure
....9.25 CH CRL Observation Connective Tissue Disease - Rheumatic Disease
....9.26 CH CRL Observation Creasman Grading System
....9.27 CH CRL Observation DSSplus
....9.28 CH CRL Observation Date of Incidence
....9.29 CH CRL Observation Dementia
....9.30 CH CRL Observation Diabetes Mellitus
....9.31 CH CRL Observation EBV
....9.32 CH CRL Observation Elston/Ellis Grading System
....9.33 CH CRL Observation FIGO Staging
....9.34 CH CRL Observation Gleason Biopsy Second Most Common or Highest Grade
....9.35 CH CRL Observation Gleason Biopsy Most Common Grade
....9.36 CH CRL Observation Gleason Excision Second Most Common or Highest Grade
....9.37 CH CRL Observation Gleason Excision Most Common Grade
....9.38 CH CRL Observation Gleason Score
....9.39 CH CRL Observation β-hCG
....9.40 CH CRL Observation HIV/AIDS
....9.41 CH CRL Observation HPV/p16
....9.42 CH CRL Observation Hemiplegia / Paraplegia
....9.43 CH CRL Observation Her2 Receptor Status
....9.44 CH CRL Observation ICCC-3 Code
....9.45 CH CRL Observation ICCC-3 Extended Code
....9.46 CH CRL Observation ICCC-3 Main Group
....9.47 CH CRL Observation ICD-10
....9.48 CH CRL Observation ICD-O-3 Behaviour
....9.49 CH CRL Observation ICD-O-3 Histological Grade
....9.50 CH CRL Observation ICD-O-3 Laterality
....9.51 CH CRL Observation ICD-O-3 Morphology
....9.52 CH CRL Observation ICD-O-3 Morphology Post-transformation
....9.53 CH CRL Observation ICD-O-3 Morphology Pre-transformation
....9.54 CH CRL Observation ICD-O-3 Topography
....9.55 CH CRL Observation INRGSS Staging
....9.56 CH CRL Observation IRSS Staging
....9.57 CH CRL Observation ISS Staging
....9.58 CH CRL Observation LDH
....9.59 CH CRL Observation Liver Disease
....9.60 CH CRL Observation Lugano Staging
....9.61 CH CRL Observation Lymphatic Invasion
....9.62 CH CRL Observation Metastases at Diagnosis Indicator
....9.63 CH CRL Observation Microsatellite Instability
....9.64 CH CRL Observation Moderate to Severe Chronic Kidney Disease
....9.65 CH CRL Observation Myocardial Infarction
....9.66 CH CRL Observation Number of Examined Regional Lymph Nodes
....9.67 CH CRL Observation Number of Examined Sentinel Lymph Nodes
....9.68 CH CRL Observation Number of Involved Regional Lymph Nodes
....9.69 CH CRL Observation Number of Positive Sentinel Lymph Nodes
....9.70 CH CRL Observation Oestrogen Receptor Status
....9.71 CH CRL Observation pM
....9.72 CH CRL Observation pN
....9.73 CH CRL Observation PRETEXT Staging
....9.74 CH CRL Observation pT
....9.75 CH CRL Observation Pathological Tumour Size
....9.76 CH CRL Observation Peptic Ulcer Disease
....9.77 CH CRL Observation Perineural Invasion
....9.78 CH CRL Observation Peripheral Vascular Disease
....9.79 CH CRL Observation Pretreatment Prostate Specific Antigen
....9.80 CH CRL Observation Progesterone Receptor Status
....9.81 CH CRL Observation Rai Staging
....9.82 CH CRL Observation Resection Margin In-situ Tumour
....9.83 CH CRL Observation Resection Margin Invasive Tumour
....9.84 CH CRL Observation Residual In-situ Tumour
....9.85 CH CRL Observation Residual Invasive Tumour
....9.86 CH CRL Observation Rhabdomyosarcoma Site Staging
....9.87 CH CRL Observation SIOP Staging
....9.88 CH CRL Observation SalzerKuntschik Grading System
....9.89 CH CRL Observation Sentinel Lymph Node Assessment
....9.90 CH CRL Observation Serum Tumour Markers
....9.91 CH CRL Observation Shimada Grading System
....9.92 CH CRL Observation St. Jude / Murphy Staging
....9.93 CH CRL Observation TNM Stage Group
....9.94 CH CRL Observation Topography of Metastases at Diagnosis
....9.95 CH CRL Observation Topography of Post-diagnosis Metastases
....9.96 CH CRL Observation Toronto Tier II (Manual) Staging
....9.97 CH CRL Observation Tumour Proliferation Labeling
....9.98 CH CRL Observation Type of Recurrence/Transformation
....9.99 CH CRL Observation Venous Invasion
....9.100 CH CRL Observation WHO(CNS) Grading System
....9.101 CH CRL Observation WHO Grade Group
....9.102 CH CRL Observation a-Prefix of pTNM
....9.103 CH CRL Observation m-Suffix of pT
....9.104 CH CRL Observation y-Prefix of cTNM
....9.105 CH CRL Observation y-Prefix of pTNM
....9.106 CH CRL Organization
....9.107 CH CRL Organization Department
....9.108 CH CRL Patient
....9.109 CH CRL Practitioner
....9.110 CH CRL Procedure Diagnostic Method
....9.111 CH CRL Procedure Method of First Detection
....9.112 CH CRL Procedure Treatment
....9.113 CH CRL Function of Contact Person Extension
....9.114 CH CRL Procedure Treatment Goal
....9.115 NKRS - α-fetoprotein
....9.116 NKRS - Ann Arbor Staging
....9.117 NKRS - Basis of First Treatment Complex Decision
....9.118 NKRS - Binet Staging
....9.119 NKRS - COG ALL Staging
....9.120 NKRS - COG Staging
....9.121 NKRS - Circumferential Resection Margins
....9.122 NKRS - Creasman Grading System
....9.123 NKRS - DSSplus
....9.124 NKRS - Diabetes Mellitus
....9.125 NKRS - Diagnostic Methods Used
....9.126 NKRS - Elston/Ellis Grading System
....9.127 NKRS - FIGO Staging
....9.128 NKRS - β-hCG
....9.129 NKRS - Her2 Receptor Status
....9.130 NKRS - ICCC-3 Code
....9.131 NKRS - ICCC-3 Extended Code
....9.132 NKRS - ICCC-3 Main Group
....9.133 NKRS - INRGSS Staging
....9.134 NKRS - IRSS Staging
....9.135 NKRS - ISS Staging
....9.136 NKRS - ICD-O-3 Behaviour
....9.137 NKRS - ICD-O-3 Histological Grade
....9.138 NKRS - ICD-O-3 Laterality
....9.139 NKRS - LDH
....9.140 NKRS - Liver Disease
....9.141 NKRS - Lugano Staging
....9.142 NKRS - Lymphatic Invasion
....9.143 NKRS - Method of First Detection
....9.144 NKRS - PRETEXT Staging
....9.145 NKRS - Perineural Invasion
....9.146 NKRS - Rai Staging
....9.147 NKRS - Residual In-situ Tumour
....9.148 NKRS - Residual Invasive Tumour
....9.149 NKRS - Rhabdomyosarcoma Site Staging
....9.150 NKRS - SIOP Staging
....9.151 NKRS - SalzerKuntschik Grading System
....9.152 NKRS - Sentinel Lymph Node Assessment
....9.153 NKRS - Serum Tumour Markers
....9.154 NKRS - Shimada Grading System
....9.155 NKRS - St. Jude / Murphy Staging
....9.156 NKRS - TNM Stage Group
....9.157 NKRS - Topography of Metastases
....9.158 NKRS - Toronto Tier II (Manual) Staging
....9.159 NKRS - Treatment Goal
....9.160 NKRS - Type of Recurrence/Transformation
....9.161 NKRS - Venous Invasion
....9.162 NKRS - WHO(CNS) Grading System
....9.163 NKRS - WHO Grade Group
....9.164 NKRS - cM
....9.165 NKRS - cN
....9.166 NKRS - cT
....9.167 NKRS - m-Suffix of pT
....9.168 NKRS - pM
....9.169 NKRS - pN
....9.170 NKRS - pT
....9.171 NKRS - α-fetoprotein
....9.172 NKRS - Ann Arbor Staging
....9.173 NKRS - Basis of First Treatment Complex Decision
....9.174 NKRS - Binet Staging
....9.175 NKRS - COG ALL Staging
....9.176 NKRS - COG Staging
....9.177 NKRS - Circumferential Resection Margins
....9.178 NKRS - Creasman Grading System
....9.179 NKRS - DSSplus
....9.180 NKRS - Diabetes Mellitus
....9.181 NKRS - Diagnostic Methods Used
....9.182 NKRS - Elston/Ellis Grading System
....9.183 NKRS - FIGO Staging
....9.184 NKRS - β-hCG
....9.185 NKRS - Her2 Receptor Status
....9.186 NKRS - ICCC-3 Code
....9.187 NKRS - ICCC-3 Extended Code
....9.188 NKRS - ICCC-3 Main Group
....9.189 NKRS - INRGSS Staging
....9.190 NKRS - IRSS Staging
....9.191 NKRS - ISS Staging
....9.192 NKRS - ICD-O-3 Behaviour
....9.193 NKRS - ICD-O-3 Histological Grade
....9.194 NKRS - ICD-O-3 Laterality
....9.195 NKRS - LDH
....9.196 NKRS - Liver Disease
....9.197 NKRS - Lugano Staging
....9.198 NKRS - Lymphatic Invasion
....9.199 NKRS - Method of First Detection
....9.200 NKRS - PRETEXT Staging
....9.201 NKRS - Perineural Invasion
....9.202 NKRS - Rai Staging
....9.203 NKRS - Residual In-situ Tumour
....9.204 NKRS - Residual Invasive Tumour
....9.205 NKRS - Rhabdomyosarcoma Site Staging
....9.206 NKRS - SIOP Staging
....9.207 NKRS - SalzerKuntschik Grading System
....9.208 NKRS - Sentinel Lymph Node Assessment
....9.209 NKRS - Serum Tumour Markers
....9.210 NKRS - Shimada Grading System
....9.211 NKRS - St. Jude / Murphy Staging
....9.212 NKRS - TNM Stage Group
....9.213 NKRS - Topography of Metastases
....9.214 NKRS - Toronto Tier II (Manual) Staging
....9.215 NKRS - Type of Recurrence/Transformation
....9.216 NKRS Variables
....9.217 NKRS - Venous Invasion
....9.218 NKRS - WHO Grade Group
....9.219 NKRS - cM
....9.220 NKRS - cN
....9.221 NKRS - cT
....9.222 NKRS - m-Suffix of pT
....9.223 NKRS - pM
....9.224 NKRS - pN
....9.225 NKRS - pT
....9.226 Abteilung Gastroenterologie
....9.227 Abteilung Minimum
....9.228 Abteilung Onkologie
....9.229 Abteilung Pathologie
....9.230 Agnes Bauer
....9.231 α-fetoprotein - AFP1
....9.232 α-fetoprotein - Not Performed
....9.233 α-fetoprotein - Unknown
....9.234 Ann Arbor Staging - I
....9.235 Ann Arbor Staging - I+A
....9.236 Ann Arbor Staging - Local Code
....9.237 Ann Arbor Staging - Unknown
....9.238 Associated In-situ Tumour - No
....9.239 Associated In-situ Tumour - Unknown
....9.240 Associated In-situ Tumour - Yes
....9.241 Binet Staging - B
....9.242 Binet Staging - Unknown
....9.243 Breslow Thickness - 2.0 mm
....9.244 Breslow Thickness - Unknown
....9.245 Bundle from Organization
....9.246 Bundle from Practitioner
....9.247 Bundle UC 1a Gastro (2018-12-01)
....9.248 Bundle UC 1a Gastro (2019-06-17)
....9.249 Bundle UC 1a Info (2018-12-07)
....9.250 Bundle UC 1a Ops (2018-12-14)
....9.251 Bundle UC 1a Patho (2018-12-02)
....9.252 Bundle UC 1a Patho (2018-12-15)
....9.253 Bundle UC 1b Gastro (2018-12-01)
....9.254 Bundle UC 1b Gastro (2019-06-17)
....9.255 Bundle UC 1b Info (2018-12-07)
....9.256 Bundle UC 1b Ops (2018-12-14)
....9.257 Bundle UC 1b Patho (2018-12-02)
....9.258 Bundle UC 1b Patho (2018-12-15)
....9.259 COG ALL Staging - CNS1
....9.260 COG ALL Staging - Unknown
....9.261 COG Staging - II
....9.262 COG Staging - Unknown
....9.263 Cerebrovascular Accident or Transient Ischemic Attack - No
....9.264 Cerebrovascular Accident or Transient Ischemic Attack - Yes
....9.265 Charlson Index - 8
....9.266 Chronic Pulmonary Disease - No
....9.267 Chronic Pulmonary Disease - Yes
....9.268 Circumferential Resection Margins - 0mm
....9.269 Circumferential Resection Margins - Unknown
....9.270 Clinical Tumour Size - 11 mm
....9.271 Clinical Tumour Size - Unknown
....9.272 Communication Robert Meier
....9.273 Communication Franz Minimum
....9.274 Composition from Organization
....9.275 Composition from Practitioner
....9.276 Composition UC 1a Gastro (2018-12-01)
....9.277 Composition UC 1a Gastro (2019-06-17)
....9.278 Composition UC 1a Info (2018-12-07)
....9.279 Composition UC 1a Ops (2018-12-14)
....9.280 Composition UC 1a Patho (2018-12-02)
....9.281 Composition UC 1a Patho (2018-12-15)
....9.282 Composition UC 1b Gastro (2018-12-01)
....9.283 Composition UC 1b Gastro (2019-06-17)
....9.284 Composition UC 1b Info (2018-12-07)
....9.285 Composition UC 1b Ops (2018-12-14)
....9.286 Composition UC 1b Patho 2018-12-02
....9.287 Composition UC 1b Patho (2018-12-15)
....9.288 Concomitant Disease A
....9.289 Concomitant Disease B
....9.290 Congestive Heart Failure - No
....9.291 Congestive Heart Failure - Yes
....9.292 Connective Tissue Disease - Rheumatic Disease - No
....9.293 Connective Tissue Disease - Rheumatic Disease - Yes
....9.294 Creasman Grading System - 1
....9.295 Creasman Grading System - Unknown
....9.296 DSSplus - IB
....9.297 DSSplus - Unknown
....9.298 Date of Incidence - 2018-12-02
....9.299 Date of Incidence - 2018-12-02
....9.300 Date of Incidence - 2018-12-15
....9.301 Dementia - No
....9.302 Dementia - Yes
....9.303 Diabetes Mellitus - End-organ damage
....9.304 Diabetes Mellitus - No
....9.305 Diabetes Mellitus - Uncomplicated
....9.306 Diagnostic Method - CT Scan of Tumour
....9.307 Diagnostic Method - Biopsy of Primary Tumour (2018-12-01)
....9.308 Diagnostic Method - Biopsy of Primary Tumour (2018-12-02)
....9.309 Diagnostic Method - Biopsy of Primary Tumour (2018-12-14)
....9.310 Diagnostic Method - Biopsy of Primary Tumour (2019-06-17)
....9.311 Diagnostic Method - Endoscopy (2018-12-01)
....9.312 Diagnostic Method - Endoscopy (2018-12-02)
....9.313 Diagnostic Method - Endoscopy (2019-06-17)
....9.314 Diagnostic Method - Surgical Tissue from Operation (2018-12-14)
....9.315 Diagnostic Method - Surgical Tissue from Operation (2018-12-15)
....9.316 Diagnostic Method - Unknown
....9.317 Report as PDF from Hospital Minimum
....9.318 Report as PDF from Practitioner Minimum
....9.319 Report as PDF UC 1a Gastro (2018-12-01)
....9.320 Report as PDF UC 1a Gastro (2019-06-17)
....9.321 Report as PDF UC 1a Info (2018-12-07)
....9.322 Report as PDF UC 1a Ops (2018-12-14)
....9.323 Report as PDF UC 1a Patho (2018-12-02)
....9.324 Report as PDF UC 1a Patho (2018-12-15)
....9.325 EBV - No
....9.326 EBV - Unknown
....9.327 EBV - Yes
....9.328 Else Zimmerli
....9.329 Elston/Ellis Grading System - 2
....9.330 Elston/Ellis Grading System - Unknown
....9.331 Emma Minimum
....9.332 FIGO Staging - I
....9.333 FIGO Staging - IIIA1i
....9.334 FIGO Staging - Unknown
....9.335 Final Cause of Death
....9.336 Final Cause of Death - Local Code
....9.337 Franz Minimum
....9.338 Gleason Biopsy Most Common Grade - 2
....9.339 Gleason Biopsy Second Most Common or Highest Grade - 3
....9.340 Gleason Excision Most Common Grade - 3
....9.341 Gleason Excision Second Most Common or Highest Grade - 3
....9.342 Gleason Score - 6
....9.343 Gleason Score - Unknown
....9.344 β-hCG - Not Performed
....9.345 β-hCG - Unknown
....9.346 β-hCG - hCG2
....9.347 HIV/AIDS - No
....9.348 HIV/AIDS - Yes
....9.349 HPV/p16 - No
....9.350 HPV/p16 - Unknown
....9.351 HPV/p16 - Yes
....9.352 Hemiplegia / Paraplegia - No
....9.353 Hemiplegia / Paraplegia - Yes
....9.354 Her2 Receptor Status - Not Performed
....9.355 Her2 Receptor Status - Overexpressed
....9.356 Her2 Receptor Status - Unknown
....9.357 ICCC-3 Code - VIIIa
....9.358 ICCC-3 Extended Code - Ia.4
....9.359 ICCC-3 Extended Code - Not Applicable
....9.360 ICCC-3 Main Group - VIII
....9.361 ICD-10 - C25
....9.362 ICD-10 - Kolon (2018-12-02)
....9.363 ICD-10 - Kolon (preliminary)
....9.364 ICD-O-3 Behaviour - Malignant
....9.365 ICD-O-3 Behaviour - Malignant (2018-12-02)
....9.366 ICD-O-3 Behaviour - Malignant (2018-12-15)
....9.367 ICD-O-3 Histological Grade - Grade III (2018-12-02)
....9.368 ICD-O-3 Histological Grade - Grade III (2018-12-15)
....9.369 ICD-O-3 Histological Grade - Unknown
....9.370 ICD-O-3 Laterality - Unilateral, NOS
....9.371 ICD-O-3 Laterality - NA (2018-12-02)
....9.372 ICD-O-3 Laterality - NA (2018-12-15)
....9.373 ICD-O-3 Morphology - Adenokarzinom
....9.374 ICD-O-3-Morphology - Muzinöses Adenokarzinom (2018-12-02)
....9.375 ICD-O-3 Morphology - Muzinöses Adenokarzinom (2018-12-15)
....9.376 ICD-O-3 Topography - Pankreaskörper
....9.377 ICD-O-3 Topography - Flexura hepatica (2018-12-02)
....9.378 ICD-O-3 Topography - Flexura hepatica (2018-12-15)
....9.379 ICD-O-3 Morphology Post-transformation - 9861/3
....9.380 ICD-O-3 Morphology Pre-transformation - 9950/3
....9.381 INRGSS Staging - M
....9.382 INRGSS Staging - Unknown
....9.383 IRSS Staging - Unknown
....9.384 IRSS Staging - cIVa.1
....9.385 ISS Staging - II
....9.386 ISS Staging - Unknown
....9.387 LDH - LDH3
....9.388 LDH - Not Performed
....9.389 LDH - Unknown
....9.390 Liver Disease - Mild
....9.391 Liver Disease - Moderate to Severe
....9.392 Liver Disease - No
....9.393 Lugano Staging - I
....9.394 Lugano Staging - Unknown
....9.395 Lymphatic invasion - L0
....9.396 Lymphatic invasion - L1 (2018-12-02)
....9.397 Lymphatic invasion - L1 (2018-12-15)
....9.398 Metastases at Diagnosis Indicator - No
....9.399 Metastases at Diagnosis Indicator - Unknown
....9.400 Metastases at Diagnosis Indicator - Yes
....9.401 Method of First Detection - Clinical Symptoms
....9.402 Method of First Detection - Unknown
....9.403 Microsatellite Instability - No
....9.404 Microsatellite Instability - Unknown
....9.405 Microsatellite Instability - Yes
....9.406 Moderate to Severe Chronic Kidney Disease - No
....9.407 Moderate to Severe Chronic Kidney Disease - Yes
....9.408 Myocardial Infarction - No
....9.409 Myocardial Infarction - Yes
....9.410 Number of Examined Regional Lymph Nodes - 7
....9.411 Number of Examined Regional Lymph Nodes - 18 (2018-12-02)
....9.412 Number of Examined Regional Lymph Nodes - 18 (2018-12-15)
....9.413 Number of Examined Regional Lymph Nodes - Unknown
....9.414 Number of Examined Sentinel Lymph Nodes - 4
....9.415 Number of Examined Sentinel Lymph Nodes - Unknown
....9.416 Number of Involved Regional Lymph Nodes - 2
....9.417 Number of Involved Regional Lymph Nodes - 0 (2018-12-02)
....9.418 Number of Involved Regional Lymph Nodes - 0 (2018-12-15)
....9.419 Number of Involved Regional Lymph Nodes - Unknown
....9.420 Number of Positive Sentinel Lymph Nodes - 6
....9.421 Number of Positive Sentinel Lymph Nodes - Unknown
....9.422 Oestrogen Receptor Status - 5 %
....9.423 Oestrogen Receptor Status - Not Performed
....9.424 Oestrogen Receptor Status - Positive
....9.425 Oestrogen Receptor Status - Unknown
....9.426 PRETEXT Staging - II
....9.427 PRETEXT Staging - Unknown
....9.428 Pathological Tumour Size - 11 mm
....9.429 Pathological Tumour Size - Unknown
....9.430 Peptic Ulcer Disease - No
....9.431 Peptic Ulcer Disease - Yes
....9.432 Perineural invasion - Pn0
....9.433 Perineural invasion - Pn0 (2018-12-02)
....9.434 Perineural invasion - Pn0 (2018-12-15)
....9.435 Peripheral Vascular Disease - No
....9.436 Peripheral Vascular Disease - Yes
....9.437 Pretreatment Prostate Specific Antigen - 80 ng/ml
....9.438 Pretreatment Prostate Specific Antigen - Unknown
....9.439 Primary disease
....9.440 Progesterone Receptor Status - 3 %
....9.441 Progesterone Receptor Status - Negative
....9.442 Progesterone Receptor Status - Not Performed
....9.443 Progesterone Receptor Status - Unknown
....9.444 Rai Staging - II
....9.445 Rai Staging - Unknown
....9.446 Resection Margin In-situ Tumour - 2.0 mm
....9.447 Resection Margin In-situ Tumour - Not Applicable
....9.448 Resection Margin In-situ Tumour - Unknown
....9.449 Resection Margin Invasive Tumour - 0.3 mm
....9.450 Resection Margin Invasive Tumour - Not Applicable
....9.451 Resection Margin Invasive Tumour - Unknown
....9.452 Residual In-situ Tumour - R1
....9.453 Residual In-situ Tumour - Unknown
....9.454 Residual Invasive Tumour - R0
....9.455 Residual Invasive Tumour - Unknown
....9.456 Rhabdomyosarcoma Site Staging - I
....9.457 Rhabdomyosarcoma Site Staging - Unknown
....9.458 Robert Meier
....9.459 SIOP Staging - Unknown
....9.460 SIOP Staging - yIII
....9.461 SalzerKuntschik Grading System - 1
....9.462 SalzerKuntschik Grading System - Unknown
....9.463 Secondary Disease
....9.464 Sentinel Lymph Node Assessment - N0
....9.465 Sentinel Lymph Node Assessment - Unknown
....9.466 Serum Tumour Markers - Not Performed
....9.467 Serum Tumour Markers - S3
....9.468 Serum Tumour Markers - Unknown
....9.469 Shimada Grading System - 1
....9.470 Shimada Grading System - Unknown
....9.471 Spital Minimum
....9.472 Spital Seeblick Doktor Gastro
....9.473 Spital Seeblick Doktor Patho
....9.474 Spital Seeblick Hans Egli
....9.475 St. Jude / Murphy Staging - I
....9.476 St. Jude / Murphy Staging - Unknown
....9.477 TNM Stage Group - Stage IV
....9.478 TNM Stage Group - Stage I (2018-12-02)
....9.479 TNM Stage Group - Stage IIA (2018-12-15)
....9.480 Topography of Metastases at Diagnosis - LYM
....9.481 Topography of Metastases at Diagnosis - MAR
....9.482 Topography of Metastases at Diagnosis - OTH
....9.483 Topography of Metastases at Diagnosis - Unknown
....9.484 Topography of Post-diagnosis Metastases - HEP
....9.485 Topography of Post-diagnosis Metastases - Unknown
....9.486 Toronto Tier II (Manual) Staging - II
....9.487 Toronto Tier II (Manual) Staging - Unknown
....9.488 Treatment - Intraoperative Application of Chemotherapeutic Substances
....9.489 Treatment Decision - Tumour Board 2018-12-15
....9.490 Tumour Proliferation Labeling - 3 %
....9.491 Tumour Proliferation Labeling - Unknown
....9.492 Type of Recurrence/Transformation - Metastasis
....9.493 Type of Recurrence/Transformation - Progression
....9.494 Type of Recurrence/Transformation - Relapse
....9.495 Type of Recurrence/Transformation - Relapse (2019-06-17)
....9.496 Type of Recurrence/Transformation - Transformation
....9.497 Type of Recurrence/Transformation - Unknown
....9.498 Venous Invasion - V1
....9.499 Venous Invasion - V0 (2018-12-02)
....9.500 Venous Invasion - V0 (2018-12-15)
....9.501 WHO(CNS) Grading System - 3
....9.502 WHO(CNS) Grading System - Unknown
....9.503 WHO Grade Group - Grade Group 2
....9.504 WHO Grade Group - Unknown
....9.505 a-Prefix of pTNM - Yes
....9.506 a-Prefix of pTNM - No (2018-12-02)
....9.507 a-Prefix of pTNM - No (2018-12-15)
....9.508 cM - cM0
....9.509 cM - NA (2018-12-02)
....9.510 cM - NA (2018-12-15)
....9.511 cN - cN2
....9.512 cN - NA (2018-12-02)
....9.513 cN - NA (2018-12-15)
....9.514 cT - cT1
....9.515 cT - NA (2018-12-02)
....9.516 cT - NA (2018-12-15)
....9.517 m-Suffix of pT - 4
....9.518 m-Suffix of pT - Unknown (2018-12-02)
....9.519 m-Suffix of pT - Unknown (2018-12-15)
....9.520 m-Suffix of pT - Unknown
....9.521 m-Suffix of pT - Unspecified Multiplicity
....9.522 pM - Unknown (2018-12-02)
....9.523 pM - Unknown (2018-12-15)
....9.524 pM - Unknown
....9.525 pN - pN1(sn)
....9.526 pN - pN0 (2018-12-02)
....9.527 pN - pN0 (2018-12-15)
....9.528 pT - pT1b2
....9.529 pT - pT1 (2018-12-02)
....9.530 pT - pT3 (2018-12-15)
....9.531 y-Prefix of cTNM - No
....9.532 y-Prefix of cTNM - No (2018-12-02)
....9.533 y-Prefix of cTNM - No (2018-12-15)
....9.534 y-Prefix of pTNM - Yes
....9.535 y-Prefix of pTNM - No (2018-12-02)
....9.536 y-Prefix of pTNM - No (2018-12-15)